Primary Hyperoxaluria Diagnosis and Management

Overview of Primary Hyperoxaluria

Primary hyperoxaluria (PH) is a group of rare, autosomal‑recessive metabolic disorders that lead to excessive endogenous production of oxalate. The excess oxalate combines with calcium to form calcium‑oxalate crystals, which can precipitate in the kidneys, urinary tract, and, in advanced disease, systemic tissues. Early recognition and targeted management are essential to prevent irreversible renal damage and systemic oxalosis.

Initial Metabolic Evaluation in Children with Nephrolithiasis

Key Clinical Scenario

A 4‑year‑old boy presents with right flank pain, macroscopic hematuria, a 0.8 cm renal pelvic stone, and bilateral medullary hyperechogenicity on ultrasound.

Best Initial Test

Collect urine for oxalate/creatinine ratio and citrate.

This non‑invasive test identifies hyperoxaluria and hypocitraturia, the two most common metabolic drivers of stone formation in children.

• Why urine first? Metabolic abnormalities are often the root cause; imaging or empirical citrate therapy should follow a confirmed metabolic diagnosis.
• Mnemonic: U‑C‑C – Urine, Creatinine, Citrate.

Other options such as 24‑hour calcium measurement, CT imaging, or immediate citrate therapy are secondary and may miss the underlying metabolic defect.

Enzymatic Defects in Primary Hyperoxaluria Types

Type 1: The Classic Form

Deficiency of alanine‑glyoxylate aminotransferase (AGT) in hepatic peroxisomes.

AGT normally converts glyoxylate to glycine, preventing its conversion to oxalate. When AGT is absent or mis‑localized, glyoxylate accumulates and is oxidized to oxalate.

• Location: Peroxisomes of hepatocytes.
• Mnemonic: “AlGT – AlGa in the Peroxisome of the Fígado.”

Type 2 and Type 3

While the focus of this course is Type 1, brief distinctions are useful:

• Type 2 results from mutations in HOGA1, affecting the mitochondrial enzyme 4‑hydroxy‑2‑oxoglutarate aldolase.
• Type 3 involves defects in the glycolate oxidase (GO) gene, leading to increased glycolate conversion to oxalate.
• Urinary L‑glycerate elevation is a clue for Type 2, not Type 1.

Targeted Therapies for Primary Hyperoxaluria Type 1

Pyridoxine (Vitamin B6) – The First‑Line Rescue

Patients with the homozygous p.Gly170Arg mutation in the AGXT gene often benefit from high‑dose pyridoxine. Vitamin B6 acts as a co‑factor that stabilizes the mis‑targeted AGT enzyme, allowing partial restoration of its peroxisomal localization and activity.

• Dosage: 5–10 mg/kg/day divided into 2–3 doses.
• Monitoring: Urinary oxalate/creatinine ratio and plasma oxalate levels every 3–6 months.
• Outcome: Up to 30 % of patients achieve a meaningful reduction in oxalate production.

RNA‑Based Therapies

Two siRNA agents have transformed the therapeutic landscape:

• Lumasiran – Silences glycolate oxidase (GO) messenger RNA, reducing glycolate conversion to oxalate. By lowering substrate availability, it indirectly reduces oxalate burden.
• Nedosiran – Targets lactate dehydrogenase 5 (LDH5) in the liver, directly decreasing oxalate synthesis. Currently approved for PH Type 1 only.

Both agents are administered subcutaneously and have demonstrated significant reductions in urinary oxalate excretion in phase III trials.

Diagnostic Pitfalls in Advanced Kidney Disease

Why 24‑Hour Urinary Oxalate Is Unreliable in Dialysis Patients

When eGFR falls below ~30 mL/min, renal clearance of oxalate drops dramatically. Consequently, urinary oxalate excretion declines, even though plasma oxalate may be markedly elevated. In dialysis‑dependent patients, plasma oxalate accumulation drives systemic oxalosis, making urine measurements misleading.

• Key point: Urinary oxalate falls sharply when eGFR < 30 mL/min.
• Clinical implication: Rely on plasma oxalate levels (>30–50 µmol/L) to assess systemic burden.

Renal Biopsy Findings

The definitive histologic hallmark of oxalate deposition is the presence of birefringent calcium‑oxalate crystals under polarized light. These crystals appear rhomboid or needle‑shaped and produce a characteristic bright‑white reflection.

• Other findings such as IgG deposits, uric acid crystals, or interstitial fibrosis are non‑specific and do not confirm oxalate disease.

Clinical Thresholds for Systemic Oxalosis

Plasma oxalate concentrations exceeding 30–50 µmol/L are associated with the onset of systemic oxalosis in patients with advanced chronic kidney disease (CKD). At this level, oxalate precipitates in extra‑renal tissues, leading to bone pain, cardiomyopathy, and cutaneous deposits.

Regular monitoring of plasma oxalate is recommended for PH patients who reach CKD stage 3 or higher, especially when eGFR < 30 mL/min.

Putting It All Together: A Practical Algorithm

1. Initial presentation with stones or renal calcifications
   • Order urine oxalate/creatinine ratio and citrate.
   • If hyperoxaluria confirmed, proceed to genetic testing for AGXT, GRHPR, and HOGA1.
2. Genetic confirmation of PH Type 1
   • Start high‑dose pyridoxine if the mutation is pyridoxine‑responsive (e.g., p.Gly170Arg).
   • Consider lumasiran or nedosiran if oxalate remains elevated despite pyridoxine.
3. Renal function monitoring
   • Track eGFR every 3–6 months.
   • When eGFR < 30 mL/min, measure plasma oxalate; values > 30 µmol/L signal systemic risk.
4. Advanced disease
   • Consider combined liver‑kidney transplantation for refractory cases.
   • Maintain high fluid intake (> 2 L/day) and citrate supplementation to inhibit crystal formation.

Adhering to this algorithm improves outcomes, reduces stone recurrence, and delays progression to end‑stage renal disease.

Key Take‑Home Messages

• Urine oxalate/creatinine ratio and citrate are the first‑line tests for suspected metabolic stone disease in children.
• Primary Hyperoxaluria Type 1 is caused by AGT deficiency in hepatic peroxisomes.
• Pyridoxine rescues mis‑targeted AGT in many patients with the p.Gly170Arg mutation.
• In CKD stage 3 or dialysis, plasma oxalate > 30–50 µmol/L, not urinary oxalate, predicts systemic oxalosis.
• Lumasiran silences glycolate oxidase mRNA, while nedosiran targets LDH5, both lowering oxalate production.
• Birefringent calcium‑oxalate crystals on polarized renal biopsy confirm oxalate deposition.

Understanding these concepts equips clinicians to diagnose early, apply targeted therapies, and monitor for complications in primary hyperoxaluria.